Cytopia begins Phase II
Thursday, 04 September, 2008
Cytopia [ASX: CYT] has commenced enrolment for its Phase 1b/II study of CYT997 for brain cancer.
CYT997 is a vascular disrupting agent being tested in patients with the aggressive brain cancer glioblastoma multiforme.
Around 30 patients will be involved in the study, which will be conducted at a number of clinical centres in Australia and overseas. CYT997 will be used in combination with two other marketed anticancer agents.
Glioblastomas often resurface even after surgical resection or radiation therapy, but are highly vascular and dependent on their own abnormal blood supply for growth. CYT997 is aimed at disrupting this supply.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
